Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
Yoav H. Messinger(Children’s Minnesota - St. Paul Hospital), Bruce Bostrom(Minnesota West Community & Technical College), Elena Eckroth(Children's Hospital of Los Angeles), Richard Sposto(Children's Hospital of Los Angeles), Jemily Malvar(University of Southern California), Paul S. Gaynon(University of Southern California), Jeannette van der Giessen(Children's Hospital of Los Angeles)
Cited by 205
Related Papers
The genetic landscape of high-risk neuroblastoma
|Nature Genetics|2013|1.2k
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|920
Outcome of Treatment in Children with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2000|599
The treatment of medulloblastoma
|Journal of neurosurgery|1990|583